[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab
Immune checkpoint inhibitors have changed the paradigm of cancer treatment; however, non-invasive biomarkers of response are still needed to identify candidates for non-responders. We aimed to investigate whether immunotherapy [18F]FDG PET radiomics signature (iRADIOMICS) predicts response of metast...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2020-07-01
|
| Series: | Radiology and Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/raon-2020-0042 |
| _version_ | 1818729513275621376 |
|---|---|
| author | Valentinuzzi Damijan Vrankar Martina Boc Nina Ahac Valentina Zupancic Ziga Unk Mojca Skalic Katja Zagar Ivana Studen Andrej Simoncic Urban Eickhoff Jens Jeraj Robert |
| author_facet | Valentinuzzi Damijan Vrankar Martina Boc Nina Ahac Valentina Zupancic Ziga Unk Mojca Skalic Katja Zagar Ivana Studen Andrej Simoncic Urban Eickhoff Jens Jeraj Robert |
| author_sort | Valentinuzzi Damijan |
| collection | DOAJ |
| description | Immune checkpoint inhibitors have changed the paradigm of cancer treatment; however, non-invasive biomarkers of response are still needed to identify candidates for non-responders. We aimed to investigate whether immunotherapy [18F]FDG PET radiomics signature (iRADIOMICS) predicts response of metastatic non-small-cell lung cancer (NSCLC) patients to pembrolizumab better than the current clinical standards. |
| first_indexed | 2024-12-17T22:47:05Z |
| format | Article |
| id | doaj.art-d1a7de5e0bc54812b8a34cc844fcea3e |
| institution | Directory Open Access Journal |
| issn | 1581-3207 |
| language | English |
| last_indexed | 2024-12-17T22:47:05Z |
| publishDate | 2020-07-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Radiology and Oncology |
| spelling | doaj.art-d1a7de5e0bc54812b8a34cc844fcea3e2022-12-21T21:29:47ZengSciendoRadiology and Oncology1581-32072020-07-0154328529410.2478/raon-2020-0042raon-2020-0042[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumabValentinuzzi Damijan0Vrankar Martina1Boc Nina2Ahac Valentina3Zupancic Ziga4Unk Mojca5Skalic Katja6Zagar Ivana7Studen Andrej8Simoncic Urban9Eickhoff Jens10Jeraj Robert11Jožef Stefan Institute, Ljubljana, SloveniaInstitute of Oncology Ljubljana, Ljubljana, SloveniaInstitute of Oncology Ljubljana, Ljubljana, SloveniaInstitute of Oncology Ljubljana, Ljubljana, SloveniaInstitute of Oncology Ljubljana, Ljubljana, SloveniaInstitute of Oncology Ljubljana, Ljubljana, SloveniaInstitute of Oncology Ljubljana, Ljubljana, SloveniaInstitute of Oncology Ljubljana, Ljubljana, SloveniaJožef Stefan Institute, Ljubljana, SloveniaJožef Stefan Institute, Ljubljana, SloveniaDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USAJožef Stefan Institute, Ljubljana, SloveniaImmune checkpoint inhibitors have changed the paradigm of cancer treatment; however, non-invasive biomarkers of response are still needed to identify candidates for non-responders. We aimed to investigate whether immunotherapy [18F]FDG PET radiomics signature (iRADIOMICS) predicts response of metastatic non-small-cell lung cancer (NSCLC) patients to pembrolizumab better than the current clinical standards.https://doi.org/10.2478/raon-2020-0042anti-pd-1[18f]fdg pet/ctnon-small-cell lung cancerradiomics analysisiradiomics |
| spellingShingle | Valentinuzzi Damijan Vrankar Martina Boc Nina Ahac Valentina Zupancic Ziga Unk Mojca Skalic Katja Zagar Ivana Studen Andrej Simoncic Urban Eickhoff Jens Jeraj Robert [18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab Radiology and Oncology anti-pd-1 [18f]fdg pet/ct non-small-cell lung cancer radiomics analysis iradiomics |
| title | [18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab |
| title_full | [18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab |
| title_fullStr | [18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab |
| title_full_unstemmed | [18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab |
| title_short | [18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab |
| title_sort | 18f fdg pet immunotherapy radiomics signature iradiomics predicts response of non small cell lung cancer patients treated with pembrolizumab |
| topic | anti-pd-1 [18f]fdg pet/ct non-small-cell lung cancer radiomics analysis iradiomics |
| url | https://doi.org/10.2478/raon-2020-0042 |
| work_keys_str_mv | AT valentinuzzidamijan 18ffdgpetimmunotherapyradiomicssignatureiradiomicspredictsresponseofnonsmallcelllungcancerpatientstreatedwithpembrolizumab AT vrankarmartina 18ffdgpetimmunotherapyradiomicssignatureiradiomicspredictsresponseofnonsmallcelllungcancerpatientstreatedwithpembrolizumab AT bocnina 18ffdgpetimmunotherapyradiomicssignatureiradiomicspredictsresponseofnonsmallcelllungcancerpatientstreatedwithpembrolizumab AT ahacvalentina 18ffdgpetimmunotherapyradiomicssignatureiradiomicspredictsresponseofnonsmallcelllungcancerpatientstreatedwithpembrolizumab AT zupancicziga 18ffdgpetimmunotherapyradiomicssignatureiradiomicspredictsresponseofnonsmallcelllungcancerpatientstreatedwithpembrolizumab AT unkmojca 18ffdgpetimmunotherapyradiomicssignatureiradiomicspredictsresponseofnonsmallcelllungcancerpatientstreatedwithpembrolizumab AT skalickatja 18ffdgpetimmunotherapyradiomicssignatureiradiomicspredictsresponseofnonsmallcelllungcancerpatientstreatedwithpembrolizumab AT zagarivana 18ffdgpetimmunotherapyradiomicssignatureiradiomicspredictsresponseofnonsmallcelllungcancerpatientstreatedwithpembrolizumab AT studenandrej 18ffdgpetimmunotherapyradiomicssignatureiradiomicspredictsresponseofnonsmallcelllungcancerpatientstreatedwithpembrolizumab AT simoncicurban 18ffdgpetimmunotherapyradiomicssignatureiradiomicspredictsresponseofnonsmallcelllungcancerpatientstreatedwithpembrolizumab AT eickhoffjens 18ffdgpetimmunotherapyradiomicssignatureiradiomicspredictsresponseofnonsmallcelllungcancerpatientstreatedwithpembrolizumab AT jerajrobert 18ffdgpetimmunotherapyradiomicssignatureiradiomicspredictsresponseofnonsmallcelllungcancerpatientstreatedwithpembrolizumab |